[Therapy of non-Hodgkin lymphomas].
The survey is introduced by references to the relations between special diagnostic findings and life expectancy. Also the contribution of the clinician to the diagnostics of the non-Hodgkin-lymphomas is dealt with. Five standpoints are to be regarded in the new management of chemotherapy: 1. The polychemotherapy is more effective than the monotherapy. 2. Massive-dose therapies of middle degree are more favourable than frequent, low-dosed cytostatic dosages. 3. Connection of the polychemotherapy with the radiotherapy in stage III and IV. 4. Particularly in the lymphomas with a high degree of malignancy polychemotherapy already in stage II following the radiation. 5. Especially intensive polychemotherapy in the lymphomas with a high degree of malignancy. The hitherto got findings in the polychemotherapy of the non-Hodgkin-lymphomas are reported. Here particularly the COP-scheme proved to be favourable, if necessary in connection with bleomycin, adriamycin or methotrexat; also BCNU or dakarbacin are possible. Own propositions, separated for lymphomas for low and high malignancy, respectively, take into consideration also the GDR-preparation Cytostasan.